{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:30:03Z","timestamp":1790127003134,"version":"4.0.1"},"reference-count":200,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T00:00:00Z","timestamp":1570924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, Portugal","award":["PTDC\/MED-QUI\/31721\/2017"],"award-info":[{"award-number":["PTDC\/MED-QUI\/31721\/2017"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, Portugal","award":["UID\/DTP\/04138\/2019"],"award-info":[{"award-number":["UID\/DTP\/04138\/2019"]}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, Portugal","award":["SFRH\/BD\/117586\/2016."],"award-info":[{"award-number":["SFRH\/BD\/117586\/2016."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomaterials"],"abstract":"<jats:p>Melanoma is an aggressive form of skin cancer, being one of the deadliest cancers in the world. The current treatment options involve surgery, radiotherapy, targeted therapy, immunotherapy and the use of chemotherapeutic agents. Although the last approach is the most used, the high toxicity and the lack of efficacy in advanced stages of the disease have demanded the search for novel bioactive molecules and\/or efficient drug delivery systems. The current review aims to discuss the most recent advances on the elucidation of potential targets for melanoma treatment, such as aquaporin-3 and tyrosinase. In addition, the role of nanotechnology as a valuable strategy to effectively deliver selective drugs is emphasized, either incorporating\/encapsulating synthetic molecules or natural-derived compounds in lipid-based nanosystems such as liposomes. Nanoformulated compounds have been explored for their improved anticancer activity against melanoma and promising results have been obtained. Indeed, they displayed improved physicochemical properties and higher accumulation in tumoral tissues, which potentiated the efficacy of the compounds in pre-clinical experiments. Overall, these experiments opened new doors for the discovery and development of more effective drug formulations for melanoma treatment.<\/jats:p>","DOI":"10.3390\/nano9101455","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T03:54:13Z","timestamp":1571025253000},"page":"1455","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-4701","authenticated-orcid":false,"given":"Jacinta","family":"Oliveira Pinho","sequence":"first","affiliation":[{"name":"Research Institute for Medicines, iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-7418","authenticated-orcid":false,"given":"Mariana","family":"Matias","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines, iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6814-7226","authenticated-orcid":false,"given":"Maria Manuela","family":"Gaspar","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines, iMed.ULisboa, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11910-016-0686-x","article-title":"Chemotherapy-Related Neurotoxicity","volume":"16","author":"Taillibert","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","article-title":"Cancer-treatment-induced neurotoxicity\u2014focus on newer treatments","volume":"13","author":"Stone","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bcp.13126","article-title":"Microtubule destabilising agents: Far more than just antimitotic anticancer drugs","volume":"83","author":"Bates","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The Different Mechanisms of Cancer Drug Resistance: A Brief Review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Delou, J.M.A., Souza, A.S.O., Souza, L.C.M., and Borges, H.L. (2019). Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells, 8.","DOI":"10.3390\/cells8091013"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2019.08.034","article-title":"Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article","volume":"311\u2013312","author":"Khalifa","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_8","unstructured":"Rajitha, B., Malla, R.R., Vadde, R., Kasa, P., Prasad, G.L.V., Farran, B., Kumari, S., Pavitra, E., Kamal, M.A., and Raju, G.S.R. (2019). Horizons of nanotechnology applications in female specific cancers. Semin. Cancer Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108720","DOI":"10.1016\/j.cbi.2019.06.033","article-title":"Emerging trends in the novel drug delivery approaches for the treatment of lung cancer","volume":"309","author":"Sharma","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3892\/or.2016.5032","article-title":"Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma (Review)","volume":"36","author":"Heo","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","article-title":"BRAF\/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage","volume":"19","author":"Mar","year":"2013","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"ref_16","unstructured":"The Cancer Genome Atlas Network (2015). Genomic Classification of Cutaneous Melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.critrevonc.2012.03.002","article-title":"Cancer chemotherapy: A critical analysis of its 60 years of history","volume":"84","author":"Galmarini","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbcan.2019.02.002","article-title":"Many ways to resistance: How melanoma cells evade targeted therapies","volume":"1871","author":"Kozar","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mandal\u00e0, M., and Romano, E. (2018). Mechanisms of Drug Resistance in Melanoma. Mechanisms of Drug Resistance in Cancer Therapy, Springer.","DOI":"10.1007\/978-3-030-10507-5"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"ImmunoTargets Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2340\/00015555-2035","article-title":"Metastatic melanoma\u2014A review of current and future treatment options","volume":"95","author":"Maverakis","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2018.08.008","article-title":"The impact of effective systemic therapies on surgery for stage IV melanoma","volume":"103","author":"Smith","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","article-title":"Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years?","volume":"40","author":"Eggermont","year":"2004","journal-title":"Eur. J. Cancer (Oxford, Engl. 1990)"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1634\/theoncologist.5-2-144","article-title":"Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma","volume":"5","author":"Agarwala","year":"2000","journal-title":"Oncologist"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.tips.2013.10.003","article-title":"Challenging resistance mechanisms to therapies for metastatic melanoma","volume":"34","author":"Tentori","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","article-title":"Chemotherapy for Melanoma","volume":"Volume 167","author":"Kaufman","year":"2016","journal-title":"Melanoma. Cancer Treatment and Research"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41419-017-0059-7","article-title":"Cell death-based treatments of melanoma: Conventional treatments and new therapeutic strategies","volume":"9","author":"Mattia","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2016.12.003","article-title":"Melanoma: Last call for radiotherapy","volume":"110","author":"Espenel","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ward, W., and Farma, J. (2017). Radiation Therapy for Melanoma. Cutaneous Melanoma: Etiology and Therapy, Codon Publications.","DOI":"10.15586\/codon.cutaneousmelanoma.2017"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.critrevonc.2016.01.016","article-title":"Role of radiation therapy in melanomas: Systematic review and best practice in 2016","volume":"99","author":"Fort","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2217\/fon.14.300","article-title":"Radiotherapy for cutaneous melanoma: Current and future applications","volume":"11","author":"Gorayski","year":"2015","journal-title":"Futur. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Imunol. (Baltimore, Md. 1950)"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/EDBK_199047","article-title":"Emerging Strategies in Systemic Therapy for the Treatment of Melanoma","volume":"38","author":"Ascierto","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book. Am. Soc. Clin. Oncol. Annu. Meet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers7030860","article-title":"Targeting RTK Signaling Pathways in Cancer","volume":"7","author":"Regad","year":"2015","journal-title":"Cancers (Basel)"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejcsup.2013.07.013","article-title":"Immunotherapy of melanoma","volume":"11","author":"Haanen","year":"2013","journal-title":"EJC Suppl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2217\/imt-2017-0143","article-title":"Immunotherapy in melanoma","volume":"10","author":"Feld","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nri.2016.80","article-title":"Regulatory circuits of T cell function in cancer","volume":"16","author":"Speiser","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.seminoncol.2015.05.011","article-title":"The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment","volume":"42","author":"Gajewski","year":"2015","journal-title":"Semin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cell.2016.03.031","article-title":"Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling","volume":"165","author":"Minn","year":"2016","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fonc.2016.00233","article-title":"Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy","volume":"6","author":"Swart","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/chem.201704410","article-title":"Structure and Function of Human Tyrosinase and Tyrosinase-Related Proteins","volume":"24","author":"Lai","year":"2018","journal-title":"Chemistry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17460441.2014.907789","article-title":"Design and discovery of mushroom tyrosinase inhibitors and their therapeutic applications","volume":"9","author":"Mendes","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2174\/1568026616666160216160112","article-title":"Are Human Tyrosinase and Related Proteins Suitable Targets for Melanoma Therapy?","volume":"16","author":"Buitrago","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molonc.2011.11.001","article-title":"Aquaporins mediate the chemoresistance of human melanoma cells to arsenite","volume":"6","author":"Gao","year":"2012","journal-title":"Mol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1039\/C4MD00265B","article-title":"Gold compounds as aquaporin inhibitors: New opportunities for therapy and imaging","volume":"5","author":"Soveral","year":"2014","journal-title":"Medchemcomm"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1039\/C7BM00405B","article-title":"Cationic folate-mediated liposomal delivery of bis-arylidene oxindole induces efficient melanoma tumor regression","volume":"5","author":"Elechalawar","year":"2017","journal-title":"Biomater. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jconrel.2012.05.043","article-title":"Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor","volume":"164","author":"Lee","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1535-7163.MCT-16-0285","article-title":"Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma","volume":"16","author":"Gowda","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Jiang, F., Jin, K., Huang, S., Bao, Q., Shao, Z., Hu, X., and Ye, J. (2016). Liposomal C6 Ceramide Activates Protein Phosphatase 1 to Inhibit Melanoma Cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159849"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.nano.2017.12.020","article-title":"Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment","volume":"14","author":"Gowda","year":"2018","journal-title":"Nanomed. Nanotechnol., Biol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/2225-4110.110423","article-title":"Camptothecin-Loaded Liposomes with \u03b1-Melanocyte-Stimulating Hormone Enhance Cytotoxicity Toward and Cellular Uptake by Melanomas: An Application of Nanomedicine on Natural Product","volume":"3","author":"Lin","year":"2013","journal-title":"J. Tradit. Complement. Med."},{"key":"ref_58","first-page":"2541","article-title":"STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models","volume":"27","author":"Yu","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1002\/jps.22573","article-title":"Evaluation of Pharmacokinetic, Biodistribution, Pharmacodynamic, and Toxicity Profile of Free Juglone and Its Sterically Stabilized Liposomes","volume":"100","author":"Aithal","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.ejca.2011.12.018","article-title":"The antitumour activities induced by pegylated liposomal cytochalasin D in murine models","volume":"48","author":"Huang","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1016\/j.cub.2012.11.025","article-title":"Aquaporins","volume":"23","author":"Verkman","year":"2013","journal-title":"Curr. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.febslet.2010.04.037","article-title":"Structural insights into eukaryotic aquaporin regulation","volume":"584","author":"Hedfalk","year":"2010","journal-title":"FEBS Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.256.5055.385","article-title":"Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein","volume":"256","author":"Preston","year":"1992","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-540-79885-9_1","article-title":"Discovery of the aquaporins and development of the field","volume":"Volume 190","author":"Beitz","year":"2009","journal-title":"Aquaporins. Handbook of Experimental Pharmacology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.febslet.2012.06.013","article-title":"Aquaporins: Another piece in the osmotic puzzle","volume":"586","author":"Alleva","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_66","unstructured":"Soveral, G., Nielsen, S., and Casini, A. (2016). Aquaporins in Health and Disease: New Molecular Targets for Drug Discovery, CRC Press, Taylor & Francis Group."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Laloux, T., Junqueira, B., Maistriaux, L.C., Ahmed, J., Jurkiewicz, A., and Chaumont, F. (2018). Plant and mammal aquaporins: Same but different. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020521"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.bbagen.2013.10.039","article-title":"The role of mammalian superaquaporins inside the cell","volume":"1840","author":"Ishibashi","year":"2014","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1039\/C8MT00072G","article-title":"Aquaporins in cancer development: Opportunities for bioinorganic chemistry to contribute novel chemical probes and therapeutic agents","volume":"10","author":"Aikman","year":"2018","journal-title":"Metallomics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fphys.2018.00101","article-title":"New perspectives on the potential role of aquaporins (AQPs) in the physiology of inflammation","volume":"9","author":"Meli","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Yang, B. (2017). The evolutionary aspects of aquaporin family. Aquaporins. Advances in Experimental Medicine and Biology, Springer.","DOI":"10.1007\/978-94-024-1057-0"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.bbagen.2015.08.023","article-title":"Beyond water homeostasis: Diverse functional roles of mammalian aquaporins","volume":"1850","author":"Kitchen","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.canlet.2010.02.005","article-title":"Aquaporins in tumor growth and angiogenesis","volume":"294","author":"Nico","year":"2010","journal-title":"Cancer Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1073\/pnas.91.14.6269","article-title":"Molecular cloning and expression of a member of the aquaporin family with permeability to glycerol and urea in addition to water expressed at the basolateral membrane of kidney collecting duct cells","volume":"91","author":"Ishibashi","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.bbagen.2013.09.017","article-title":"Aquaporin-facilitated transmembrane diffusion of hydrogen peroxide","volume":"1840","author":"Bienert","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Beitz, E. (2009). Skin Aquaporins: Function in Hydration, Wound Healing, and Skin Epidermis Homeostasis. Aquaporins. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/978-3-540-79885-9"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.humpath.2006.07.015","article-title":"Expression of aquaporin 3 (AQP3) in normal and neoplastic lung tissues","volume":"38","author":"Liu","year":"2007","journal-title":"Hum. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Pelagalli, A., Squillacioti, C., Mirabella, N., and Meli, R. (2016). Aquaporins in Health and Disease: An Overview Focusing on the Gut of Different Species. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17081213"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/MCB.01482-07","article-title":"Prevention of skin tumorigenesis and impairment of epidermal cell proliferation by targeted aquaporin-3 gene disruption","volume":"28","author":"Verkman","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1128\/MCB.00971-15","article-title":"Aquaporin-3 Controls Breast Cancer Cell Migration by Regulating Hydrogen Peroxide Transport and Its Downstream Cell Signaling","volume":"36","author":"Satooka","year":"2016","journal-title":"Mol. Cell. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1002\/chem.201902121","article-title":"Unveiling the Mechanisms of Aquaglyceroporin-3 Water and Glycerol Permeation by Metadynamics","volume":"25","author":"Wragg","year":"2019","journal-title":"Chem. Eur. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1038\/ncomms8454","article-title":"Aquaporin-3-mediated hydrogen peroxide transport is required for NF-\u03baB signalling in keratinocytes and development of psoriasis","volume":"6","author":"Satooka","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.3390\/biom5042184","article-title":"Arsenic disruption of DNA damage responses\u2014Potential role in carcinogenesis and chemotherapy","volume":"5","author":"Muenyi","year":"2015","journal-title":"Biomolecules"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd4226","article-title":"Aquaporins: Important but elusive drug targets","volume":"13","author":"Verkman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1039\/C6MB00013D","article-title":"Exploring the gating mechanisms of aquaporin-3: New clues for the design of inhibitors?","volume":"12","author":"Martins","year":"2016","journal-title":"Mol. Biosyst."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ccr.2013.01.031","article-title":"Emerging protein targets for metal-based pharmaceutical agents: An update","volume":"257","author":"Oliveira","year":"2013","journal-title":"Coord. Chem. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"11911","DOI":"10.1039\/C5DT01023C","article-title":"Exploring the potential of gold(III) cyclometallated compounds as cytotoxic agents: Variations on the C^N theme","volume":"44","author":"Bertrand","year":"2015","journal-title":"Dalton Trans. (Cambridge, Engl. 2003)"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/205698a0","article-title":"Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode","volume":"205","author":"Rosenberg","year":"1965","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000149583","article-title":"The contributions of Paul Ehrlich to pharmacology: A tribute on the occasion of the centenary of his Nobel Prize","volume":"82","author":"Bosch","year":"2008","journal-title":"Pharmacology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/ejoc.201600943","article-title":"Ru III Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic","volume":"2017","author":"Riccardi","year":"2017","journal-title":"Eur. J. Org. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1038\/s41598-019-43411-3","article-title":"Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer","volume":"9","author":"Piccolo","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1021\/cr400460s","article-title":"Metallodrugs in Medicinal Inorganic Chemistry","volume":"8","author":"Mjos","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/med.20168","article-title":"Gold compounds as anticancer agents: Chemistry, cellular pharmacology, and preclinical studies","volume":"30","author":"Nobili","year":"2010","journal-title":"Med. Res. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ardp.200600151","article-title":"Non platinum metal complexes as anti-cancer drugs","volume":"340","author":"Ott","year":"2007","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/cmdc.201300107","article-title":"Aquaporin inhibition by gold(III) compounds: New insights","volume":"8","author":"Martins","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/jcp.24632","article-title":"Functional inhibition of aquaporin-3 with a gold-based compound induces blockage of cell proliferation","volume":"229","author":"Serna","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2217\/nnm-2016-0086","article-title":"Nanoformulations of a potent copper-based aquaporin inhibitor with cytotoxic effect against cancer cells","volume":"11","author":"Nave","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1039\/C7MT00271H","article-title":"On the toxicity and transport mechanisms of cisplatin in kidney tissues in comparison to a gold-based cytotoxic agent","volume":"9","author":"Spreckelmeyer","year":"2017","journal-title":"Metallomics"},{"key":"ref_99","first-page":"199","article-title":"7. Medicinal Chemistry of Gold Anticancer Metallodrugs","volume":"Volume 18","author":"Sigel","year":"2018","journal-title":"Metallo-Drugs: Development and Action of Anticancer Agents"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/acs.inorgchem.8b03233","article-title":"Insights into the Mechanisms of Aquaporin-3 Inhibition by Gold(III) Complexes: The Importance of Non-Coordinative Adduct Formation","volume":"58","author":"Wenzel","year":"2019","journal-title":"Inorg. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2217\/nnm-2018-0388","article-title":"Copper complex nanoformulations featuring highly promising therapeutic potential in murine melanoma models","volume":"14","author":"Pinho","year":"2019","journal-title":"Nanomedicine (Lond)"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/cr400135x","article-title":"Advances in copper complexes as anticancer agents","volume":"114","author":"Santini","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1039\/C6CC08100B","article-title":"A Cu(ii) complex targeting the translocator protein: In vitro and in vivo antitumor potential and mechanistic insights","volume":"53","author":"Montagner","year":"2017","journal-title":"Chem. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1021\/acs.inorgchem.6b01884","article-title":"Copper(II) Complexes of Phenanthroline and Histidine Containing Ligands: Synthesis, Characterization and Evaluation of their DNA Cleavage and Cytotoxic Activity","volume":"55","author":"Leite","year":"2016","journal-title":"Inorg. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"108789","DOI":"10.1016\/j.cbi.2019.108789","article-title":"Unlike reactivity of mono- and binuclear imine-copper(II) complexes toward melanoma cells via a tyrosinase-dependent mechanism","volume":"311","author":"Nunes","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/cr900247m","article-title":"Activation of DNA carbon-hydrogen bonds by metal complexes","volume":"110","author":"Pitie","year":"2010","journal-title":"Chem. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.tiv.2011.05.008","article-title":"Genotoxicity of the copper antineoplastic coordination complexes casiopeinas","volume":"25","year":"2011","journal-title":"Toxicol. Vitr."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.2174\/092986710793213751","article-title":"Copper compounds in cancer chemotherapy","volume":"17","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.compbiolchem.2018.11.021","article-title":"Identification of Casiopeina II-gly secondary targets through a systems pharmacology approach","volume":"78","author":"Hur","year":"2019","journal-title":"Comput. Biol. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/acschembio.5b00513","article-title":"[Cu(o-phthalate)(phenanthroline)] exhibits unique superoxide-mediated NCI-60 chemotherapeutic action through genomic DNA damage and mitochondrial dysfunction","volume":"11","author":"Slator","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"11997","DOI":"10.1039\/C5DT00899A","article-title":"Fluorescent mixed ligand copper(ii) complexes of anthracene-appended Schiff bases: Studies on DNA binding, nuclease activity and cytotoxicity","volume":"44","author":"Jaividhya","year":"2015","journal-title":"Dalton Trans."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jinorgbio.2011.01.006","article-title":"Tumor cytotoxicity of 5,6-dimethyl-1,10-phenanthroline and its corresponding gold(III) complex","volume":"105","author":"Wein","year":"2011","journal-title":"J. Inorg. Biochem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1039\/C5CS00132C","article-title":"Chemical biology of anticancer gold(III) and gold(I) complexes","volume":"44","author":"Zou","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Yeo, C.I., Ooi, K.K., and Tiekink, E.R.T. (2018). Gold-based medicine: A paradigm shift in anti-cancer therapy?. Molecules, 23.","DOI":"10.3390\/molecules23061410"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0021-9258(18)54108-9","article-title":"The mercury-sensitive residue at cysteine 189 in the CHIP28 water channel","volume":"268","author":"Preston","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jmb.2007.02.070","article-title":"Structural basis of aquaporin inhibition by mercury","volume":"368","author":"Savage","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0014-5793(02)03581-0","article-title":"New potent inhibitors of aquaporins: Silver and gold compounds inhibit aquaporins of plant and human origin","volume":"531","author":"Niemietz","year":"2002","journal-title":"FEBS Lett."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"12059","DOI":"10.1021\/bi901762y","article-title":"Rapid and reversible inhibition of aquaporin-4 by zinc","volume":"48","author":"Yukutake","year":"2009","journal-title":"Biochemistry"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"51939","DOI":"10.1074\/jbc.M407645200","article-title":"Copper inhibits the water and glycerol permeability of aquaporin-3","volume":"279","author":"Zelenina","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.mam.2012.01.002","article-title":"Aquaporins in drug discovery and pharmacotherapy","volume":"33","author":"Huber","year":"2012","journal-title":"Mol. Asp. Med."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Martins, A.P., Marrone, A., Ciancetta, A., Gal\u00e1n Cobo, A., Echevarr\u00eda, M., Moura, T.F., Re, N., Casini, A., and Soveral, G. (2012). Targeting aquaporin function: Potent inhibition of aquaglyceroporin-3 by a gold-based compound. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037435"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1039\/C7CC00318H","article-title":"The mechanism of aquaporin inhibition by gold compounds elucidated by biophysical and computational methods","volume":"53","author":"Wragg","year":"2017","journal-title":"Chem. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4155\/fmc-2018-9999","article-title":"Special focus: Metals in medicine","volume":"10","author":"Spencer","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jinorgbio.2016.09.013","article-title":"Selective speciation improves efficacy and lowers toxicity of platinum anticancer and vanadium antidiabetic drugs","volume":"165","author":"Doucette","year":"2016","journal-title":"J. Inorg. Biochem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1586\/edm.10.70","article-title":"Update on the regulation of mammalian melanocyte function and skin pigmentation","volume":"6","author":"Kondo","year":"2011","journal-title":"Expert Rev. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Ward, W.H., and Farma, J.M. (2017). Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective. Cutaneous Melanoma: Etiology and Therapy, Codon Publications.","DOI":"10.15586\/codon.cutaneousmelanoma.2017"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14756366.2016.1256882","article-title":"Skin whitening agents: Medicinal chemistry perspective of tyrosinase inhibitors","volume":"32","author":"Pillaiyar","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14756366.2018.1545767","article-title":"A comprehensive review on tyrosinase inhibitors","volume":"34","author":"Zolghadri","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/0277-5379(91)90319-9","article-title":"Melanogenesis: A realistic target for antimelanoma therapy?","volume":"27","author":"Riley","year":"1991","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.mayocp.2014.02.009","article-title":"Melanoma resistance: A bright future for academicians and a challenge for patient advocates","volume":"89","author":"Slominski","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0968-0896(99)00126-1","article-title":"Melanocyte-directed enzyme prodrug therapy (MDEPT): Development of a targeted treatment for malignant melanoma","volume":"7","author":"Jordan","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1016\/j.ejmech.2009.03.025","article-title":"Dopamine- and tyramine-based derivatives of triazenes: Activation by tyrosinase and implications for prodrug design","volume":"44","author":"Perry","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2013.09.040","article-title":"Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines","volume":"70","author":"Monteiro","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: Design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0968-0896(01)00039-6","article-title":"Melanocyte-Directed enzyme prodrug therapy (MDEPT): Development of second generation prodrugs for targeted treatment of malignant melanoma","volume":"9","author":"Jordan","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/S0968-0896(02)00097-4","article-title":"Synthesis and analysis of urea and carbamate prodrugs as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT)","volume":"10","author":"Jordan","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1039\/b506404j","article-title":"New prodrugs derived from 6-aminodopamine and 4-aminophenol as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT)","volume":"3","author":"Knaggs","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1600-0749.2006.00295.x","article-title":"Mechanistic studies of melanogenesis: The influence of N-substitution on dopamine quinone cyclization","volume":"19","author":"Borovansky","year":"2006","journal-title":"Pigment. Cell Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejmech.2013.10.080","article-title":"Synthesis and analysis of activity of a potential anti-melanoma prodrug with a hydrazine linker","volume":"71","author":"Mazurek","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1016\/j.bmc.2017.04.049","article-title":"The selective cytotoxicity of new triazene compounds to human melanoma cells","volume":"25","author":"Sousa","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-2836(65)80093-6","article-title":"Diffusion of univalent ions across the lamellae of swollen phospholipids","volume":"13","author":"Bangham","year":"1965","journal-title":"J. Mol. Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0014-5793(71)80109-6","article-title":"Enzyme entrapment in liposomes","volume":"14","author":"Gregoriadis","year":"1971","journal-title":"FEBS Lett."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/1061186X.2017.1365878","article-title":"Polymer therapeutics and the EPR effect","volume":"25","author":"Maeda","year":"2017","journal-title":"J. Drug Target."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.actbio.2016.12.004","article-title":"Near-infrared light triggered drug delivery system for higher efficacy of combined chemo-photothermal treatment","volume":"51","author":"Chen","year":"2017","journal-title":"Acta Biomater."},{"key":"ref_145","first-page":"55","article-title":"Targeting tumor microenvironment: Crossing tumor interstitial fluid by multifunctional nanomedicines","volume":"4","author":"Omidi","year":"2014","journal-title":"BioImpacts BI"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","article-title":"Nanomedicine therapeutic approaches to overcome cancer drug resistance","volume":"65","author":"Markman","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: Entering the mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0168-3659(01)00309-1","article-title":"Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS","volume":"74","author":"Maeda","year":"2001","journal-title":"J. Control. Release"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.drudis.2018.08.009","article-title":"Nanoengineered delivery systems for cancer imaging and therapy: Recent advances, future directions and patent evaluation","volume":"24","author":"Nabil","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Su, Y.L., and Hu, S.H. (2018). Functional Nanoparticles for Tumor Penetration of Therapeutics. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040193"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"White, B.D., Duan, C., and Townley, H.E. (2019). Nanoparticle Activation Methods in Cancer Treatment. Biomolecules, 9.","DOI":"10.3390\/biom9050202"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.biopha.2017.10.135","article-title":"Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: A biodistribution study","volume":"97","author":"Monteiro","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.colsurfb.2017.11.006","article-title":"pH-Sensitive mesoporous silica nanoparticles for chemo-photodynamic combination therapy","volume":"161","author":"Yan","year":"2018","journal-title":"Coll. Surf. B Biointerfaces"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijpharm.2017.06.069","article-title":"Engineering of multifunctional temperature-sensitive liposomes for synergistic photothermal, photodynamic, and chemotherapeutic effects","volume":"528","author":"Tran","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"7474","DOI":"10.1038\/s41598-017-06980-9","article-title":"Optimization of magneto-thermally controlled release kinetics by tuning of magnetoliposome composition and structure","volume":"7","author":"Virk","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s13346-017-0448-6","article-title":"Ultrasound-based triggered drug delivery to tumors","volume":"8","author":"Jain","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Silva, C.O., Pinho, J.O., Lopes, J.M., Almeida, A.J., Gaspar, M.M., and Reis, C. (2019). Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11010022"},{"key":"ref_159","first-page":"571394","article-title":"Targeted Delivery of Nanomedicines","volume":"2012","year":"2012","journal-title":"ISRN Pharmacol."},{"key":"ref_160","unstructured":"Pathak, Y., and Thassu, D. (2009). Formulation of NPDDS for Macromolecules. Drug Delivery Nanoparticles: Formulation and Characterization, Informa Healthcare."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1089\/jamp.2011.0928","article-title":"Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats","volume":"25","author":"Gaspar","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.1021\/acs.chemrev.5b00046","article-title":"New developments in liposomal drug delivery","volume":"115","author":"Pattni","year":"2015","journal-title":"Chem. Rev."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Lamichhane, N., Udayakumar, T.S., D\u2019Souza, W.D., Simone, C.B., Raghavan, S.R., Polf, J., and Mahmood, J. (2018). Liposomes: Clinical applications and potential for image-guided drug delivery. Molecules, 23.","DOI":"10.3390\/molecules23020288"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal formulations in clinical use: An updated review. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2217\/nnm.13.118","article-title":"Current trends in the use of liposomes for tumor targeting","volume":"8","author":"Deshpande","year":"2013","journal-title":"Nanomedicine (Lond.)"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/156802608783955629","article-title":"Developments on drug delivery systems for the treatment of mycobacterial infections","volume":"8","author":"Gaspar","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.nano.2015.06.008","article-title":"Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems","volume":"11","author":"Gaspar","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"705265","DOI":"10.1155\/2013\/705265","article-title":"Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting","volume":"2013","author":"Perche","year":"2013","journal-title":"J. Drug Deliv."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijantimicag.2007.08.008","article-title":"Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis","volume":"31","author":"Gaspar","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_172","first-page":"17","article-title":"Nanomedicines: Exploring the past, present and future","volume":"18","author":"Perrie","year":"2017","journal-title":"Drug Discov. World"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.colsurfb.2016.11.042","article-title":"Study of the pH-sensitive mechanism of tumor-targeting liposomes","volume":"151","author":"Fan","year":"2017","journal-title":"Colloid. Surf. B Biointerfaces"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.addr.2003.10.038","article-title":"On the formulation of pH-sensitive liposomes with long circulation times","volume":"56","author":"Fonseca","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejpb.2015.01.030","article-title":"Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery","volume":"91","author":"Xu","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"151","DOI":"10.17219\/acem\/60879","article-title":"The nanopharmacology and nanotoxicology of nanomaterials: New opportunities and challenges","volume":"25","author":"Radomska","year":"2016","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ijc.30708","article-title":"Recent developments in nanomedicine for melanoma treatment","volume":"141","author":"Tang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3109\/10717544.2013.861042","article-title":"Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent","volume":"22","author":"Parise","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1556-276X-6-482","article-title":"Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate","volume":"6","author":"Abreu","year":"2011","journal-title":"Nanoscale Res. Lett."},{"key":"ref_180","first-page":"1730","article-title":"A new antitumoral Heteroarylaminothieno[3,2-b]pyridine derivative: Its incorporation into liposomes and interaction with proteins monitored by fluorescence","volume":"13","author":"Costa","year":"2014","journal-title":"Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.jidsp.5640196","article-title":"Sulfur Containing Tyrosine Analogs Can Cause Selective Melanocytotoxicity Involving Tyrosinase-Mediated Apoptosis","volume":"4","author":"Minamitsuji","year":"1999","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1349-7006.2006.00382.x","article-title":"4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma","volume":"98","author":"Ito","year":"2007","journal-title":"Cancer Sci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10717544.2011.595840","article-title":"Formulation of plumbagin loaded long circulating pegylated liposomes: In vivo evaluation in C57BL\/6J mice bearing B16F1 melanoma","volume":"18","author":"Udupa","year":"2011","journal-title":"Drug Deliv."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2012.05.042","article-title":"In vitro and in vivo evaluation of N,N,N-trimethylphytosphingosine-iodide (TMP) in liposomes for the treatment of angiogenesis and metastasis","volume":"434","author":"Song","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_185","first-page":"1577","article-title":"Potential antitumor activity of novel DODAC\/PHO-S liposomes","volume":"11","author":"Saraiva","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"de Lima Luna, A.C., Santos Filho, J.R., Filho, O.M.R., Hesse, G.O., Neto, S.C., Chierice, G.O., and Maria, D.A. (2018). Modulation of pro-apoptotic effects and mitochondrial potential on B16F10 cells by DODAC\/PHO-S liposomes. BMC Res. Notes, 11.","DOI":"10.1186\/s13104-018-3170-7"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1158\/1078-0432.CCR-07-1035","article-title":"Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Nonliposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts","volume":"13","author":"Zamboni","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Gao, H.W., Chang, K.F., Huang, X.F., Lin, Y.L., Weng, J.C., Liao, K.W., and Tsai, N.M. (2018). Antitumor Effect of n-Butylidenephthalide Encapsulated on B16\/F10 Melanoma Cells In Vitro with a Polycationic Liposome Containing PEI and Polyethylene Glycol Complex. Molecules, 23.","DOI":"10.3390\/molecules23123224"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1158\/1535-7163.MCT-14-0357","article-title":"Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma","volume":"13","author":"Gowda","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3109\/13880209.2013.771376","article-title":"Inhibitory effect of liposome-encapsulated anthocyanin on melanogenesis in human melanocytes","volume":"51","author":"Hwang","year":"2013","journal-title":"Pharm. Biol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10534-010-9312-6","article-title":"Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells","volume":"23","author":"Roseanu","year":"2010","journal-title":"BioMetals"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1248\/bpb.27.1465","article-title":"Inhibitory Effects of Extracts from Peels of Citrus natsudaidai Encapsulated in Hybrid Liposomes on the Growth of Tumor Cells in Vitro","volume":"27","author":"Kadota","year":"2004","journal-title":"Biol. Pharm. Bull."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"9816","DOI":"10.1021\/acs.langmuir.6b02402","article-title":"Influence of Lipid Core Material on Physicochemical Characteristics of an Ursolic Acid-Loaded Nanostructured Lipid Carrier: An Attempt To Enhance Anticancer Activity","volume":"32","author":"Nahak","year":"2016","journal-title":"Langmuir"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13046-019-1383-9","article-title":"A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells","volume":"38","author":"Orienti","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.biopha.2014.01.004","article-title":"Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung","volume":"68","author":"Athawale","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"118609","DOI":"10.1016\/j.ijpharm.2019.118609","article-title":"A solid lipid nanoparticle formulation of 4-(N)-docosahexaenoyl 2\u2032, 2\u2032-difluorodeoxycytidine with increased solubility, stability, and antitumor activity","volume":"570","author":"Valdes","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2019.07.025","article-title":"Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment","volume":"309","author":"Bariwal","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.2217\/nnm-2019-0074","article-title":"Nano-encapsulated tryptanthrin derivative for combined anticancer therapy via inhibiting indoleamine 2,3-dioxygenase and inducing immunogenic cell death","volume":"14","author":"Yang","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jconrel.2010.10.017","article-title":"Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug","volume":"155","author":"Shim","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/bit.23048","article-title":"A unique and potent protein binding nature of liposome containing polyethylenimine and polyethylene Glycol: A nondisplaceable property","volume":"108","author":"Liu","year":"2011","journal-title":"Biotechnol. Bioeng."}],"container-title":["Nanomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-4991\/9\/10\/1455\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:25:55Z","timestamp":1760189155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-4991\/9\/10\/1455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,13]]},"references-count":200,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["nano9101455"],"URL":"https:\/\/doi.org\/10.3390\/nano9101455","relation":{},"ISSN":["2079-4991"],"issn-type":[{"value":"2079-4991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,13]]}}}